Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019Narcolepsy Therapeutics Market to Show Overall Low Growth until 2019
By: Rajesh Gunnam Rate (CAGR) of 16.9% from 2006-2011, mainly driven by the increased uptake of Provigil (modafinil) in the market and launch of Nuvigil (armodafinil) 0.6%, the market value is expected to increase to $820.9m by 2019. The overall growth of the market is expected to be low, characterized by market share wars, during the forecast period. The primary reason for the restricted growth of the narcolepsy therapeutics market is the entry of generics for Provigil in 2012. The entry of generics will lead to increased price competitiveness in the market, thereby impacting the market valuations. Provigil was the first approved product for treating Excessive Day Time Sleepiness (EDS) in narcolepsy and has the highest share in the narcolepsy therapeutics market. Though its patent expiry is in 2014, the generic entry will be in 2012, which will lead to a decrease in market valuations. However, the impact of the genericization is expected to only restrict the market during 2012-2014. The expected launch of a Phase III pipeline product by Bioprojet SCR, BF2.649 (pitolisant) GlobalData’s analysis demonstrates that the narcolepsy therapeutics developmental pipeline is weak, with only six molecules in various phases of development. There is one late stage molecule, BF2.649, which is a first-in-class product and is expected to launch during the forecast period (2011-2019). In Phase II there are three molecules. Of the six molecules in the pipeline, four of them are first-in class, while the exact mechanism of action of two products (C-10291 and flumazenil) is not available. There is no molecule in Phase I, and there is only one molecule in both the pre-clinical and discovery stages. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The current competitive scenario is strong, as the market is well served with the current approved products, generics and off-label drugs. The current approved drugs Provigil and Nuvigil have good safety and efficacy profiles, leading to moderate unmet need for EDS in the narcolepsy market. However, there still exists significant unmet need for cataplexy associated with narcolepsy as there is only single approved product, Xyrem (sodium oxybate) for the treatment of cataplexy; while antidepressants are used off-label. GlobalData, the industry analysis specialist, has released its new report, “Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Narcolepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number